다발성 경색성 치매 시장 규모, 점유율 및 성장 분석 : 진단별, 치료별, 약제 클래스별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Multi-Infarct Dementia Market size was valued at USD 2.68 Billion in 2024 and is poised to grow from USD 2.86 Billion in 2025 to USD 4.85 Billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The Global Multi-Infarct Dementia Market encompasses drugs, diagnostics, and care services aimed at mitigating vascular dementia linked to multiple infarcts, a condition representing around 20% of global dementia cases. The escalating prevalence of cardiovascular risk factors like hypertension and diabetes contributes to increased cerebral infarction rates, driving market growth. Recent studies reveal a rise in incidence, leading insurers and governments to invest in early-detection initiatives. Companies are responding with intensified R&D efforts, particularly in neuroprotective agents targeting ischemic pathways. The advent of advanced neuroimaging and biomarker tools, enabled by AI-driven automation, has revolutionized diagnostics, allowing for earlier identification of infarct-related pathologies. This innovation enhances therapeutic responsiveness and attracts investment in personalized dementia care, prompting regulatory adjustments in reimbursement policies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multi-Infarct Dementia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multi-Infarct Dementia Market Segments Analysis

Global multi-infarct dementia market is segmented by diagnosis, treatment, drug class, end user, distribution channel and region. Based on diagnosis, the market is segmented into Neuroimaging, Cognitive Assessment and Laboratory Testing. Based on treatment, the market is segmented into Drug Therapy, Cognitive Rehabilitation and Supportive Care. Based on drug class, the market is segmented into Cholinesterase Inhibitors, NMDA Receptor Antagonists and Antihypertensive Agents. Based on end user, the market is segmented into Hospitals, Neurology Clinics and Long-Term Care Facilities. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multi-Infarct Dementia Market

The increasing global life expectancy contributes to a growing elderly population, which is inherently more susceptible to vascular injuries that can result in multi-infarct dementia. As more individuals surpass the typical ages associated with stroke risk, the likelihood of experiencing multiple cerebral infarctions rises, leading to a heightened need for diagnostic, therapeutic, and long-term care options. In response, healthcare providers enhance their service offerings, while pharmaceutical and device manufacturers ramp up their research and development efforts, driving market growth. This ongoing trend also prompts policymakers to invest more resources into preventive initiatives, thereby bolstering overall market dynamics.

Restraints in the Global Multi-Infarct Dementia Market

The Global Multi-Infarct Dementia market faces significant constraints due to the high costs associated with advanced diagnostic tools and specialized treatment protocols. These financial burdens impact both healthcare providers and patients, making it challenging for many to access necessary care. In various areas, inadequate reimbursement systems exacerbate the issue, leading healthcare institutions to favor more affordable treatment options. This economic obstacle restricts the uptake of relevant products and services, particularly in low- and middle-income regions where budget limitations heavily influence healthcare decisions. Furthermore, the requirement for continuous support for caregivers adds to the overall costs of treatment, hindering broader market adoption.

Market Trends of the Global Multi-Infarct Dementia Market

The Global Multi-Infarct Dementia market is experiencing a significant transformation driven by the integration of advanced neuroimaging biomarkers. Clinicians are increasingly adopting sophisticated techniques, such as diffusion tensor imaging and functional MRI, to detect vascular lesions indicative of cognitive decline at earlier stages. This trend not only enhances early diagnosis and patient stratification for clinical trials but also enables personalized therapeutic interventions tailored to individual lesion profiles. The focus on improving prognostic accuracy is fostering collaborative research networks that promote shared imaging protocols, thereby expediting the incorporation of scientific advancements into everyday clinical practice across global healthcare systems.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Multi-Infarct Dementia Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Neuroimaging
• Cognitive Assessment
• Laboratory Testing

Global Multi-Infarct Dementia Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Drug Therapy
• Cognitive Rehabilitation
• Supportive Care

Global Multi-Infarct Dementia Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Antihypertensive Agents

Global Multi-Infarct Dementia Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Neurology Clinics
• Long-Term Care Facilities

Global Multi-Infarct Dementia Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Multi-Infarct Dementia Market Size & CAGR (2026-2033)

• North America (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • US
  • Canada
• Europe (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, Drug Class, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations